{"title":"Apple Watch测量心脏病患者心血管指标的准确性：观察性研究","authors":"Alaa Abdulhafiz Khushhal, Ashraf Abdelaal Mohamed, Mahmoud Elshahat Elsayed","doi":"10.5334/gh.1456","DOIUrl":null,"url":null,"abstract":"<p><p>The validity of Apple Watch for measuring heart rate (HR) and oxygen saturation (SpO<sub>2</sub>) in patients with cardiac diseases is still unclear. Therefore, this study aimed to investigate the accuracy of the Apple Watch in measuring HR and SpO<sub>2</sub> in patients with cardiac diseases. A cross-sectional study recruited 260 cardiac patients, including 190 with regular heart rhythm and 70 with cardiac arrhythmia. Each patient wore the Apple Watch alongside a Polar HR monitor at rest, during and after mild- to moderate-intensity exercise sessions, and wore the Apple Watch alongside a Contec pulse oximeter at rest and after exercise. The Apple Watch showed excellent validity (ICC = 0.100) in measuring the HR at rest, during mild- to moderate-intensity exercise, and after exercise in cardiac patients, as well as in measuring SpO<sub>2</sub> at rest (ICC = 0.100) and after exercise (ICC = 0.92). However, the validity of the Apple Watch for measuring SpO<sub>2</sub> decreased slightly after exercise (ICC = 0.85; good validity), especially in patients with an irregular heart rhythm. Overall, the Apple Watch appears valid for measuring HR and SpO<sub>2</sub> at rest and after exercise, and for measuring HR during mild- to moderate-intensity training in cardiac patients.</p>","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"20 1","pages":"74"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412449/pdf/","citationCount":"0","resultStr":"{\"title\":\"Accuracy of Apple Watch to Measure Cardiovascular Indices in Patients with Cardiac Diseases: Observational Study.\",\"authors\":\"Alaa Abdulhafiz Khushhal, Ashraf Abdelaal Mohamed, Mahmoud Elshahat Elsayed\",\"doi\":\"10.5334/gh.1456\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The validity of Apple Watch for measuring heart rate (HR) and oxygen saturation (SpO<sub>2</sub>) in patients with cardiac diseases is still unclear. Therefore, this study aimed to investigate the accuracy of the Apple Watch in measuring HR and SpO<sub>2</sub> in patients with cardiac diseases. A cross-sectional study recruited 260 cardiac patients, including 190 with regular heart rhythm and 70 with cardiac arrhythmia. Each patient wore the Apple Watch alongside a Polar HR monitor at rest, during and after mild- to moderate-intensity exercise sessions, and wore the Apple Watch alongside a Contec pulse oximeter at rest and after exercise. The Apple Watch showed excellent validity (ICC = 0.100) in measuring the HR at rest, during mild- to moderate-intensity exercise, and after exercise in cardiac patients, as well as in measuring SpO<sub>2</sub> at rest (ICC = 0.100) and after exercise (ICC = 0.92). However, the validity of the Apple Watch for measuring SpO<sub>2</sub> decreased slightly after exercise (ICC = 0.85; good validity), especially in patients with an irregular heart rhythm. Overall, the Apple Watch appears valid for measuring HR and SpO<sub>2</sub> at rest and after exercise, and for measuring HR during mild- to moderate-intensity training in cardiac patients.</p>\",\"PeriodicalId\":56018,\"journal\":{\"name\":\"Global Heart\",\"volume\":\"20 1\",\"pages\":\"74\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12412449/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Heart\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5334/gh.1456\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1456","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Accuracy of Apple Watch to Measure Cardiovascular Indices in Patients with Cardiac Diseases: Observational Study.
The validity of Apple Watch for measuring heart rate (HR) and oxygen saturation (SpO2) in patients with cardiac diseases is still unclear. Therefore, this study aimed to investigate the accuracy of the Apple Watch in measuring HR and SpO2 in patients with cardiac diseases. A cross-sectional study recruited 260 cardiac patients, including 190 with regular heart rhythm and 70 with cardiac arrhythmia. Each patient wore the Apple Watch alongside a Polar HR monitor at rest, during and after mild- to moderate-intensity exercise sessions, and wore the Apple Watch alongside a Contec pulse oximeter at rest and after exercise. The Apple Watch showed excellent validity (ICC = 0.100) in measuring the HR at rest, during mild- to moderate-intensity exercise, and after exercise in cardiac patients, as well as in measuring SpO2 at rest (ICC = 0.100) and after exercise (ICC = 0.92). However, the validity of the Apple Watch for measuring SpO2 decreased slightly after exercise (ICC = 0.85; good validity), especially in patients with an irregular heart rhythm. Overall, the Apple Watch appears valid for measuring HR and SpO2 at rest and after exercise, and for measuring HR during mild- to moderate-intensity training in cardiac patients.
Global HeartMedicine-Cardiology and Cardiovascular Medicine
CiteScore
5.70
自引率
5.40%
发文量
77
审稿时长
5 weeks
期刊介绍：
Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources.
Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention.
Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
